AIM
TEVA icon

Aigen Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Aigen Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-43,793
Closed -$330K – 1079
2023
Q2 		$330K Buy
+43,793
New +$355K 0.05% 457
2022
Q4 		– Sell
-206,743
Closed -$1.67M – 770
2022
Q3 		$1.67M Buy
+206,743
New +$1.83M 0.24% 125
2022
Q1 		– Sell
-54,243
Closed -$449K – 1061
2021
Q4 		$449K Buy
+54,243
New +$490K 0.03% 667
2021
Q2 		– Sell
-13,459
Closed -$155K – 725
2021
Q1 		$155K Buy
+13,459
New +$154K 0.02% 567
2020
Q1 		– Sell
-58,383
Closed -$572K – 1562
2019
Q4 		$572K Buy
+58,383
New +$521K 0.09% 294

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Aigen Investment Management's TEVA Position: Q3 2023 in Review

Aigen Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 43,793 shares — an estimated $330K sold.

Aigen Investment Management first reported a position in TEVA in Q4 2019 and held it in 5 quarters. The position peaked at $1.67M in Q3 2022. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • Aigen Investment Management reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Aigen Investment Management sold 43,793 Teva Pharmaceuticals shares in Q3 2023, an estimated $330K.
  • Aigen Investment Management first reported a position in Teva Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Aigen Investment Management's Teva Pharmaceuticals position peaked at $1.67M in Q3 2022.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Aigen Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.